Report: Largest Study Yet Shows Ivermectin Failed to Reduce Covid Hospitalizations

I’m shocked, I tell you. Shocked.

Soumyabrata Roy/NurPhoto/Getty Images

The coronavirus is a rapidly developing news story, so some of the content in this article might be out of date. Check out our most recent coverage of the coronavirus crisis, and subscribe to the Mother Jones Daily newsletter.

Antiparasitic drug Ivermectin became a partisan battleground during the Covid-19 pandemic, as anti-vaccine influencers and Republican politicians hawked it as a miracle cure, to the widespread skepticism of infectious disease experts. 

A peer-reviewed study recently presented by Dr. Edward Mills, a professor of health sciences at McMaster University in Canada, offered significant new evidence that ivermectin was coronavirus snake oil all along. 

In the largest trial yet analyzing the effectiveness of ivermectin on treating the coronavirus, Mills and his fellow researchers found that Covid-19 patients at risk of severe illness who received ivermectin did no better than those prescribed a placebo, the Wall Street Journal reported on Friday.

“This is the first large, prospective study that should really help put to rest ivermectin and not give any credibility to the use of it for Covid-19,” Peter Hotez, dean of the National School of Tropical Medicine at Baylor College of Medicine, told the Journal

Of the 1,358 patients, researchers prescribed half a three-day course of ivermectin pills, and the other half with a placebo. They then tracked how many patients were hospitalized over the course of four weeks, how quickly the patients rid the virus from their bodies, and death rates, among other variables. The researchers parsed the data in a variety of different ways and found no instances where ivermectin impacted patient outcomes.

Earlier in the pandemic, some researchers hypothesized that ivermectin could help, after a few studies appeared to show a benefit. However, research consistently failed to validate these earlier findings, and many of the original studies that started the ivermectin craze were discovered to have employed flawed methods. Nevertheless, ivermectin remained a favored treatment among the hardline, anti-vaccine flank of the Republican Party, many of whom continued to take the drug even as medical experts warned that there was no hard evidence it worked.

My colleague Kiera Butler has followed the strange journey of ivermectin from its beginnings as the follow-up act to the discredited Trump-touted malaria drug hydroxychloroquine. In January she wrote that doctors had known for more than a year that the antiparasitic drug wasn’t effective against Covid, and that the FDA had explicitly warned against prescribing it to Covid patients.

But, nevertheless, many physicians continued to prescribe the drug anyway, exacting real costs to the public in the form of sky-high insurance and Medicare expenditures: “What’s more,” Kiera wrote, “anti-vaccine activists often tout ivermectin as an alternative to vaccines—yet many Covid patients who have opted for ivermectin and other untested treatments instead of vaccines have required lengthy and expensive hospital stays.”

WE'LL BE BLUNT.

We have a considerable $390,000 gap in our online fundraising budget that we have to close by June 30. There is no wiggle room, we've already cut everything we can, and we urgently need more readers to pitch in—especially from this specific blurb you're reading right now.

We'll also be quite transparent and level-headed with you about this.

In "News Never Pays," our fearless CEO, Monika Bauerlein, connects the dots on several concerning media trends that, taken together, expose the fallacy behind the tragic state of journalism right now: That the marketplace will take care of providing the free and independent press citizens in a democracy need, and the Next New Thing to invest millions in will fix the problem. Bottom line: Journalism that serves the people needs the support of the people. That's the Next New Thing.

And it's what MoJo and our community of readers have been doing for 47 years now.

But staying afloat is harder than ever.

In "This Is Not a Crisis. It's The New Normal," we explain, as matter-of-factly as we can, what exactly our finances look like, why this moment is particularly urgent, and how we can best communicate that without screaming OMG PLEASE HELP over and over. We also touch on our history and how our nonprofit model makes Mother Jones different than most of the news out there: Letting us go deep, focus on underreported beats, and bring unique perspectives to the day's news.

You're here for reporting like that, not fundraising, but one cannot exist without the other, and it's vitally important that we hit our intimidating $390,000 number in online donations by June 30.

And we hope you might consider pitching in before moving on to whatever it is you're about to do next. It's going to be a nail-biter, and we really need to see donations from this specific ask coming in strong if we're going to get there.

payment methods

WE'LL BE BLUNT.

We have a considerable $390,000 gap in our online fundraising budget that we have to close by June 30. There is no wiggle room, we've already cut everything we can, and we urgently need more readers to pitch in—especially from this specific blurb you're reading right now.

We'll also be quite transparent and level-headed with you about this.

In "News Never Pays," our fearless CEO, Monika Bauerlein, connects the dots on several concerning media trends that, taken together, expose the fallacy behind the tragic state of journalism right now: That the marketplace will take care of providing the free and independent press citizens in a democracy need, and the Next New Thing to invest millions in will fix the problem. Bottom line: Journalism that serves the people needs the support of the people. That's the Next New Thing.

And it's what MoJo and our community of readers have been doing for 47 years now.

But staying afloat is harder than ever.

In "This Is Not a Crisis. It's The New Normal," we explain, as matter-of-factly as we can, what exactly our finances look like, why this moment is particularly urgent, and how we can best communicate that without screaming OMG PLEASE HELP over and over. We also touch on our history and how our nonprofit model makes Mother Jones different than most of the news out there: Letting us go deep, focus on underreported beats, and bring unique perspectives to the day's news.

You're here for reporting like that, not fundraising, but one cannot exist without the other, and it's vitally important that we hit our intimidating $390,000 number in online donations by June 30.

And we hope you might consider pitching in before moving on to whatever it is you're about to do next. It's going to be a nail-biter, and we really need to see donations from this specific ask coming in strong if we're going to get there.

payment methods

We Recommend

Latest

Sign up for our free newsletter

Subscribe to the Mother Jones Daily to have our top stories delivered directly to your inbox.

Get our award-winning magazine

Save big on a full year of investigations, ideas, and insights.

Subscribe

Support our journalism

Help Mother Jones' reporters dig deep with a tax-deductible donation.

Donate